JP2023510866A5 - - Google Patents
Info
- Publication number
- JP2023510866A5 JP2023510866A5 JP2022542784A JP2022542784A JP2023510866A5 JP 2023510866 A5 JP2023510866 A5 JP 2023510866A5 JP 2022542784 A JP2022542784 A JP 2022542784A JP 2022542784 A JP2022542784 A JP 2022542784A JP 2023510866 A5 JP2023510866 A5 JP 2023510866A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- cdr3
- cdr2
- cdr1
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025122880A JP2025163070A (ja) | 2020-01-13 | 2025-07-22 | 抗ｇａｌ３抗体および使用方法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062960300P | 2020-01-13 | 2020-01-13 | |
| US62/960,300 | 2020-01-13 | ||
| US202063024327P | 2020-05-13 | 2020-05-13 | |
| US63/024,327 | 2020-05-13 | ||
| US202063092069P | 2020-10-15 | 2020-10-15 | |
| US63/092,069 | 2020-10-15 | ||
| US202063122409P | 2020-12-07 | 2020-12-07 | |
| US63/122,409 | 2020-12-07 | ||
| PCT/US2021/013136 WO2021146218A1 (en) | 2020-01-13 | 2021-01-12 | Anti-gal3 antibodies and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025122880A Division JP2025163070A (ja) | 2020-01-13 | 2025-07-22 | 抗ｇａｌ３抗体および使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023510866A JP2023510866A (ja) | 2023-03-15 |
| JP2023510866A5 true JP2023510866A5 (https=) | 2024-01-22 |
Family
ID=76864188
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022542784A Pending JP2023510866A (ja) | 2020-01-13 | 2021-01-12 | 抗ｇａｌ３抗体および使用方法 |
| JP2025122880A Pending JP2025163070A (ja) | 2020-01-13 | 2025-07-22 | 抗ｇａｌ３抗体および使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025122880A Pending JP2025163070A (ja) | 2020-01-13 | 2025-07-22 | 抗ｇａｌ３抗体および使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20230036181A1 (https=) |
| EP (1) | EP4090685A4 (https=) |
| JP (2) | JP2023510866A (https=) |
| KR (1) | KR20220129030A (https=) |
| CN (2) | CN119930824A (https=) |
| AU (1) | AU2021207461A1 (https=) |
| BR (1) | BR112022013892A2 (https=) |
| CA (1) | CA3166552A1 (https=) |
| IL (1) | IL294486A (https=) |
| MX (1) | MX2022008450A (https=) |
| WO (1) | WO2021146218A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| JP7835441B2 (ja) * | 2019-12-06 | 2026-03-25 | トゥルーバインディング，インコーポレイテッド | Ｇａｌ３とインスリン受容体又はインテグリンとの相互作用を妨害する抗体及びそれらの使用方法 |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| IL308258A (en) | 2021-05-05 | 2024-01-01 | Immatics Biotechnologies Gmbh | Bma031 antigen binding polypeptides |
| JP2024526764A (ja) * | 2021-07-13 | 2024-07-19 | トゥルーバインディング，インコーポレイテッド | タンパク質凝集を防止する方法 |
| CN118524852A (zh) * | 2021-11-09 | 2024-08-20 | 真和制药有限公司 | 治疗或抑制心血管疾病的方法 |
| WO2024073511A2 (en) * | 2022-09-28 | 2024-04-04 | Truebinding, Inc. | Therapies with anti-gal3 antibodies |
| WO2025185724A1 (en) * | 2024-03-08 | 2025-09-12 | Sunmed Therapeutic Limited | Anti-galectin 3 antibodies and their use in epilepsy and related diseases |
| CN118286392A (zh) * | 2024-03-28 | 2024-07-05 | 广州医科大学附属妇女儿童医疗中心 | 重组Galectin-3在治疗慢性炎性脱髓鞘性多发性神经根神经病中的应用 |
| WO2025240949A1 (en) * | 2024-05-17 | 2025-11-20 | The Administrators Of The Tulane Educational Fund | Compositions and methods for the treatment of idiopathic pulmonary fibrosis |
| WO2025264872A1 (en) * | 2024-06-21 | 2025-12-26 | Truebinding, Inc. | Methods and compositions for treating neurodevelopmental disorders |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4792390B2 (ja) * | 2004-03-29 | 2011-10-12 | 株式会社ガルファーマ | 新規ガレクチン９改変体タンパク質及びその用途 |
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| UA104132C2 (en) * | 2007-11-13 | 2014-01-10 | Тева Биофармасьютикалз Юесей, Инк. | Humanized antibodies against tl1a |
| US8349579B2 (en) * | 2007-12-13 | 2013-01-08 | Wayne State University | Galectin-3 cleavage as a marker for matrix metalloproteinase activity in cancer |
| AU2009340423B2 (en) * | 2008-10-29 | 2014-07-24 | Bg Medicine, Inc. | Galectin-3 immunoassay |
| CA2818173C (en) * | 2010-11-30 | 2022-05-03 | Genentech, Inc. | Low affinity blood brain barrier receptor antibodies and uses therefor |
| BR112016013876B1 (pt) * | 2013-12-27 | 2022-03-22 | Eliaz Therapeutics, Inc. | Dispositivo para realização de plasmaferese |
| WO2016004093A2 (en) * | 2014-07-01 | 2016-01-07 | Stealth Biotherapeutics Corp | Therapeutic compositions including galectin-3 inhibitors and uses thereof |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| CN111201030B (zh) * | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| AU2019215202B2 (en) * | 2018-02-01 | 2025-11-13 | Memorial Sloan Kettering Cancer Center | Antibodies to Galectin-3 and methods of use thereof |
| EP3759145A4 (en) * | 2018-02-26 | 2022-03-09 | Minerva Biotechnologies Corporation | DIAGNOSTIC METHODS USING ANTI-MUC1* ANTIBODIES |
| WO2020160156A2 (en) * | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
-
2021
- 2021-01-12 BR BR112022013892A patent/BR112022013892A2/pt unknown
- 2021-01-12 EP EP21741281.6A patent/EP4090685A4/en active Pending
- 2021-01-12 MX MX2022008450A patent/MX2022008450A/es unknown
- 2021-01-12 KR KR1020227028093A patent/KR20220129030A/ko active Pending
- 2021-01-12 CA CA3166552A patent/CA3166552A1/en active Pending
- 2021-01-12 JP JP2022542784A patent/JP2023510866A/ja active Pending
- 2021-01-12 CN CN202510130333.4A patent/CN119930824A/zh active Pending
- 2021-01-12 IL IL294486A patent/IL294486A/en unknown
- 2021-01-12 CN CN202180022171.2A patent/CN115427449A/zh active Pending
- 2021-01-12 AU AU2021207461A patent/AU2021207461A1/en active Pending
- 2021-01-12 WO PCT/US2021/013136 patent/WO2021146218A1/en not_active Ceased
-
2022
- 2022-07-12 US US17/812,159 patent/US20230036181A1/en not_active Abandoned
-
2025
- 2025-01-10 US US19/017,208 patent/US20250145722A1/en active Pending
- 2025-07-22 JP JP2025122880A patent/JP2025163070A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023510866A5 (https=) | ||
| JP7195142B2 (ja) | 改善された血清アルブミン結合性免疫グロブリン可変ドメイン | |
| JP7458327B2 (ja) | 血液脳関門移動化合物及びその使用 | |
| US12384822B2 (en) | TAM receptor-binding fusion molecule having non-inflammatory phagocytosis inducing activity | |
| CN111356701B (zh) | 抗α-突触核蛋白抗体及其用途 | |
| JP6681433B2 (ja) | Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト | |
| IL294486A (en) | Antibodies against gal3 and methods of use | |
| JP2020520909A (ja) | 治療抗体の適用関連副反応の低減 | |
| WO2021110995A1 (en) | Novel molecules for therapy and diagnosis | |
| JP2023502968A (ja) | アミロイド沈着物を標的化するための修飾免疫グロブリン | |
| CN106661103A (zh) | 改进的Aβ初原纤维结合抗体 | |
| CN110719916B (zh) | 抗-trkb抗体 | |
| JP7403224B2 (ja) | 改良されたｐ２ｘ７受容体結合剤およびこれを含むポリペプチド | |
| JP2026513097A (ja) | 新規な抗ＮａＰｉ２ｂ抗体およびそれをベースとする抗体－薬物コンジュゲート、治療的方法、ならびにそれらの使用 | |
| EP4118116A1 (en) | Musk agonist antibody | |
| WO2023186078A1 (zh) | 针对c-Met的抗体及其用途 | |
| CN109152833B (zh) | 针对肌腱蛋白的人类抗体和其结合片段 | |
| CN121889428A (zh) | 抗MerTK激动剂抗体、抗MerTK双特异性抗体及其应用 | |
| HK40022840B (zh) | 抗α-突触核蛋白抗体及其用途 |